Education
About Us
Working with TipRanks
Follow Us
Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
GALT Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GALT Stock 12 Month Forecast
Average Price Target
$6.00
▲(5.08% Upside)
| Highest Price Target$6.00 | Average Price Target$6.00 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$6
Buy
5.08%
Upside
Reiterated
11/17/25
Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics' Belapectin for Fibrotic Disease TreatmentValuation and risks to price target achievement. We reiterate our Buy rating and $6 price target. Our price target is based on our clinical net present value (NPV) model, which derives its value from Galectin’s lead asset, belapectin in MASH cirrhosis and PH (100% contribution; 15% PoS) in the U.S. only. Due to preclinical status, we do not include belapectin in solid tumors in our estimates yet. The overall assumptions are located in our clinical NPV model table below. Key areas of future potential upside are based on four main factors: 1) securing further partnership agreements to develop pipeline in both U.S. and ex-U.S.
Westpark Capital
―
Hold
―
Reiterated
04/02/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$6
Buy
5.08%
Upside
Reiterated
11/17/25
Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics' Belapectin for Fibrotic Disease TreatmentValuation and risks to price target achievement. We reiterate our Buy rating and $6 price target. Our price target is based on our clinical net present value (NPV) model, which derives its value from Galectin’s lead asset, belapectin in MASH cirrhosis and PH (100% contribution; 15% PoS) in the U.S. only. Due to preclinical status, we do not include belapectin in solid tumors in our estimates yet. The overall assumptions are located in our clinical NPV model table below. Key areas of future potential upside are based on four main factors: 1) securing further partnership agreements to develop pipeline in both U.S. and ex-U.S.
Westpark Capital
―
Hold
―
Reiterated
04/02/25
Best Analysts Covering Galectin Therapeutics
1 Month
xxx
Success Rate
2/3 ratings generated profit
Average Return
+18.40%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +18.40% per trade.
3 Months
xxx
Success Rate
2/3 ratings generated profit
Average Return
+43.33%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +43.33% per trade.
1 Year
Success Rate
2/3 ratings generated profit
Average Return
+55.73%
reiterated a buy rating 26 days ago
Copying Matthew Keller's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +55.73% per trade.
2 Years
xxx
Success Rate
2/3 ratings generated profit
Average Return
+55.73%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +55.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GALT Analyst Recommendation Trends
Rating
Jan 25
Apr 25
Jun 25
Aug 25
Nov 25
Strong Buy
1
0
1
2
2
Buy
0
0
0
0
1
Hold
1
2
1
1
0
Sell
11
11
5
2
0
Strong Sell
0
0
0
0
0
total
13
13
7
5
3
Each month's total comprises the sum of three months' worth of ratings.
GALT Financial Forecast
GALT Stock Forecast FAQ
What is GALT’s average 12-month price target, according to analysts?
Based on analyst ratings, Galectin Therapeutics Inc’s 12-month average price target is 6.00.
What is GALT’s upside potential, based on the analysts’ average price target?
Galectin Therapeutics Inc has 5.08% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GALT a Buy, Sell or Hold?
Galectin Therapeutics Inc has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Galectin Therapeutics Inc’s price target?
The average price target for Galectin Therapeutics Inc is 6.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $6.00. The average price target represents 5.08% Increase from the current price of $5.71.
The highest analyst price target is $6.00 ,the lowest forecast is $6.00. The average price target represents 5.08% Increase from the current price of $5.71.
What do analysts say about Galectin Therapeutics Inc?
Galectin Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of GALT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.